Home
Technologies Available for Licensing

Technologies Available for Licensing

For Licensing Opportunities, please contact the ORTA at USArmy.Detrick.MEDCOM-USAMRMC.List.ORTA@health.mil


GENE OPTIMIZED HANTAAN VIRUS M SEGMENT DNA VACCINE FOR HEMORRHAGIC FEVER WITH RENAL SYNDROME

A synthetic, codon-optimized Hantaan virus (HTNV) full-length M gene open reading frame that consists of a unique nucleotide sequence encoding HTNV proteins. This synthetic gene was cloned into a plasmid to form the first optimized HTNV full-length M gene that elicits neutralizing antibodies in animals when delivered in combination with a similarly optimized Puumala virus (PUUV) DNA vaccine. The invention obviates the need for an extraneous gene sequence that was previously required for expression of the non-optimized HTNV gene. The synthetic gene is engineered into a molecular vaccine system to prevent hemorrhagic fever with renal syndrome (HFRS) caused by infection with HTNV, SEOV, or DOBV. Alternatively, it can be combined with the optimized PUUV DNA vaccine to protect against HFRS caused by any hantavirus.


Docket:RIID 11-37

Publication/Issued No.:9,968,669

Publication/Issue Date:2018-05-15

Categories: Method

More Detail:Visit USPTO.GOVExternal link

Lab:RIID

Inventor(s):SCHMALJOHN, C.

For Licensing Opportunities, please contact the ORTA at USArmy.Detrick.MEDCOM-USAMRMC.List.ORTA@health.mil
 
 

Last Modified Date: 25 Jul 2023

This Web site provides an introduction to the Office of Research and Technology Applications (ORTA) and contains official Government information.

Its use is intended for members of the general public, news media and Military Health System beneficiaries.

Please address questions or concerns about this Web site to the USAMRDC Public Affairs Office at:
USArmy.Detrick.MEDCOM-USAMRMC.List.ORTA@health.mil or by telephone at (301)619-2736.